CR Sanjiu sees 18% profit jump in 2024

China Resources Pharmaceutical Group Limited (HKEX: 3320) announced the principal financial information for its subsidiary, CR Sanjiu Medical & Pharmaceutical Company Limited, for the year ended December 31, 2024. CR Sanjiu reported a notable 18.05% increase in net profit attributable to shareholders, reaching RMB 3,367.89 million, compared to RMB 2,852.93 million in the previous year. Revenue also saw healthy growth, increasing by 11.63% to RMB 27,616.61 million. Basic earnings per share rose by 17.41% to RMB 2.63. The company's total assets remained relatively stable at RMB 40,081.97 million. CR Sanjiu proposes a cash dividend of RMB 3.20 (inclusive of tax) for every 10 shares and a capital reserve fund increase with every 10 shares increased by 3 shares, subject to shareholder approval at the 2024 annual general meeting.